Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Ozempic and other semaglutide medications (including Wegovy and Rybelsus) have changed the lives of millions of Americans ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...

Rybelsus is the once-daily oral formulation of Novo Nordisk's blockbuster diabetes injection Ozempic, which is taken once a week. Both treatments, as well as the company's weekly weight loss ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...